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McNelis JC, Manolopoulos KN, Gathercole LL, Bujalska IJ,
Stewart PM, Tomlinson JW, Arlt W. Dehydroepiandrosterone
exerts antiglucocorticoid action on human preadipocyte prolifera-
tion, differentiation, and glucose uptake. Am J Physiol Endocrinol
Metab 305: E1134 –E1144, 2013. First published September 10,
2013; doi:10.1152/ajpendo.00314.2012.—Glucocorticoids increase
adipocyte proliferation and differentiation, a process underpinned by
the local reactivation of inactive cortisone to active cortisol within
adipocytes catalyzed by 11-hydroxysteroid dehydrogenase type 1
(11-HSD1). The adrenal sex steroid precursor dehydroepiandros-
terone (DHEA) has been shown to inhibit 11-HSD1 in murine
adipocytes; however, rodent adrenals do not produce DHEA physio-
logically. Here, we aimed to determine the effects and underlying
mechanisms of the potential antiglucocorticoid action of DHEA and
its sulfate ester DHEAS in human preadipocytes. Utilizing a human
subcutaneous preadipocyte cell line, Chub-S7, we examined the
metabolism and effects of DHEA in human adipocytes, including
adipocyte proliferation, differentiation, 11-HSD1 expression, and
activity and glucose uptake. DHEA, but not DHEAS, significantly
inhibited preadipocyte proliferation via cell cycle arrest in the G1
phase independent of sex steroid and glucocorticoid receptor activa-
tion. 11-HSD1 oxoreductase activity in differentiated adipocytes
was inhibited by DHEA. DHEA coincubated with cortisone signifi-
cantly inhibited preadipocyte differentiation, which was assessed by
the expression of markers of early (LPL) and terminal (G3PDH)
adipocyte differentiation. Coincubation with cortisol, negating the
requirement for 11-HSD1 oxoreductase activity, diminished the
inhibitory effect of DHEA. Further consistent with glucocorticoid-
opposing effects of DHEA, insulin-independent glucose uptake was
significantly enhanced by DHEA treatment. DHEA increases basal
glucose uptake and inhibits human preadipocyte proliferation and
differentiation, thereby exerting an antiglucocorticoid action. DHEA
inhibition of the amplification of glucocorticoid action mediated by
11-HSD1 contributes to the inhibitory effect of DHEA on human
preadipocyte differentiation.
dehydroepiandrosterone; human adipogenesis; 11-hydroxysteroid
dehydrogenase type 1; insulin sensitivity
GLUCOCORTICOID EXCESS characteristically causes central obesity
and insulin resistance. The local reactivation of glucocorticoids
represents an important mechanism mediating glucocorticoid
action. The enzyme 11-hydroxysteroid dehydrogenase type 1
(11-HSD1) converts inactive cortisone (E) to active cortisol
(F) via its oxoreductase activity in a variety of tissues, impor-
tantly including liver and adipose tissue, which are major sites
involved in the regulation of insulin sensitivity. The clinical
significance of local glucocorticoid activation in the context of
the metabolic syndrome has been demonstrated conclusively
by a multitude of in vitro, in vivo, and clinical studies (12, 45).
In addition, the selective inhibition of 11-HSD1 activity is
emerging as an exciting, novel therapeutic approach in type 2
diabetes and the metabolic syndrome (40, 42).
Several of the physiological effects of glucocorticoids op-
pose those of the adrenal steroid dehydroepiandrosterone
(DHEA). DHEA and its sulfate ester DHEAS are the most
abundant steroids in the human circulation and accumulate in
adipose tissue at even greater concentrations (10–15 times
circulating levels) (4, 17). DHEA is the principal sex steroid
precursor in humans and can be converted directly to andro-
gens, whereas its sulfate ester DHEAS first requires cleavage
of the sulfate group by the enzyme steroid sulfatase (STS). In
addition to its indirect role as a steroid precursor, DHEA can
elicit direct effects in immune and vascular endothelial cells
(35), although a specific receptor has as yet not been charac-
terized. These studies have also highlighted distinct roles for
DHEA and DHEAS (16, 38).
The metabolic effects of DHEA are complex, regulated by
downstream metabolism of DHEA to sex steroids. Elevated
circulating androgen levels are a cardinal feature of the com-
mon endocrinopathy polycystic ovary syndrome, which is
associated with metabolic morbidities, including insulin resis-
tance and abdominal obesity. Conversely, numerous murine-
based studies have demonstrated that DHEA treatment has
beneficial effects on whole body composition and several
metabolic parameters, effects proposed to be attributable to its
direct action on adipocyte biology, but also on other metabolic
tissues such as muscle and liver. DHEA inhibits murine
3T3-L1 preadipocyte proliferation, differentiation, and ensuing
lipid accumulation (20, 32, 34, 43), and consistently, murine in
vivo studies have shown that DHEA retards fat accretion,
reducing body fat percentage and mass, modulates circulating
triglyceride levels, and attenuates hyperglycemia and/or hyper-
insulinaemia (9–11, 18, 28). Rodent adrenals lack the ability to
synthesize DHEA, and the validity of these findings to human
physiology is questionable. Recently, it was shown that DHEA
inhibits proliferation in PAZ6 preadipocytes, a cell line derived
from human brown adipose tissue, and adipogenesis in omental
but not subcutaneous preadipocytes (39), highlighting possible
depot-specific effects of DHEA. However, human in vivo trials
have proved less conclusive, and human in vitro studies are
limited (44).
Interestingly, the expression and activity of 11-HSD1 is
inhibited by DHEA in murine adipocytes (2, 43) and rat liver
(22), providing a potential mechanism by which the effects of
DHEA oppose those of glucocorticoids. The aim of this study
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was twofold; first, provide a comprehensive analysis of DHEA
metabolism in human adipocytes and the effects of DHEA and
DHEAS on human adipogenesis, and second, examine the
effect of DHEA on 11-HSD1 in human adipocytes and
resulting glucocorticoid reactivation based on our hypothesis
that DHEA inhibits adipogenesis via 11-HSD1.
RESEARCH DESIGN AND METHODS
Chub-S7 Cell Model Validation
The Chub-S7 cell line (Nestlé Research Centre, Lausanne, Swit-
zerland) was derived from human subcutaneous adipose tissue by
coexpression of human telomerase reverse transcriptase and papillo-
mavirus E7 oncoprotein (HPV-E7) genes (14) and has previously
been characterized in detail showing expression of typical white
adipose tissue markers upon differentiation (6, 14, 19). Further char-
acterization was undertaken to exclude a brown adipose tissue (BAT)
phenotype as a result of rosiglitazone treatment during Chub-S7
differentiation (see below). We compared expression of the BAT
marker uncoupling protein 1 (UCP1) (15) between Chub-S7 cells
before and after differentiation, mature human subcutaneous adi-
pocytes, and human primary-differentiated subcutaneous preadi-
pocytes with or without the presence of DHEA and primary human
hepatocytes as well as in primary mouse BAT, white adipose tissue,
and hepatocytes. Subcutaneous human adipose tissue was obtained via
the Human Biomaterials Resource Centre of the University of Bir-
mingham from donors undergoing elective open abdominal surgery at
the Queen Elizabeth Hospital Birmingham. All donors gave written
informed consent as approved by the South Birmingham (UK) Re-
search Ethics Committee. Tissue was immediately transferred from
the operating theater to the laboratory in sterile containers, and mature
adipocytes and preadipocytes were obtained after tissue digestion with
collagenase (Sigma-Aldrich, St. Louis, MO) as described before (23).
Primary mature adipocytes were left floating for 24 h in serum-free
DMEM-F-12 before mRNA extraction. Primary preadipocytes were
cultured in six-well plates in differentiation medium [containing
DMEM-F-12, 10% fetal calf serum (FCS), 33 M biotin, 17 M
pantothenic acid, 0.2 nM triiodothyronine (T3), 166 nM insulin, 45
mM methyl-3-isobutylxanthine, and 100 nM cortisol; all reagents
were from Sigma] for 5 days and then in growth medium (DMEM-
F-12, FCS, biotin, pantothenic acid, T3, insulin, and cortisol as before)
until day 14, when mRNA was extracted. DHEA (100 nM or 10 M)
was added from day 0 in treated cells. Primary human hepatocytes
were obtained from Celsis (Brussels, Belgium), and mRNA was
extracted after 24-h culture in proprietary medium (InVitroGRO;
Celsis). Mouse tissues were obtained from BL6 wild-type mice kept
in our laboratory, and mRNA was extracted from fresh tissues. All
data are shown in mean arbitrary units (AU)  SE.
Cell Culture Conditions
Chub-S7 cells were maintained in DMEM-F-12 supplemented with
10% FCS. At 48 h postconfluence, differentiation was initiated by
incubation with DMEM-F-12 supplemented with 33 M biotin, 17
M pantothenic acid, 0.2 nM T3, 167 nM insulin, 500 nM cortisol or
cortisone, and 1 M rosiglitazone for 21 days. On day 7, 14 and 21
photographs were taken to document cell morphology.
Human primary preadipocytes isolated from subcutaneous adipose
tissue were obtained from Zen-Bio (Research Triangle Park, NC).
Cells were maintained and differentiation induced according to the
manufacturer’s protocol. Briefly, preadipocytes were cultured to con-
fluence in DMEM supplemented with 10% FCS and differentiation
induced by incubation with proprietary differentiation medium (Zen-
Bio) for 7 days. Cells were then cultured with proprietary adipose
maintenance medium (Zen-Bio) for an additional 7 days.
Proliferation Assays
Tritiated thymidine uptake assay. Chub-S7 preadipocytes and hu-
man primary preadipocytes were seeded into a 24-well plate at
densities 1  105 and 2.5  105 respectively. Following overnight
culture, medium was supplemented with DHEA, androstenediol, or
DHEAS (0–100 M; Sigma-Aldrich). Following 24-, 48-, or 72 h
incubation, cell proliferation was assessed by incubation with radio-
labeled thymidine (0.2 Ci/well) for the final 6 h of culture. Proteins
were precipitated with TCA, and cells were scraped in NaOH. The
respective content of radiolabeled nuclear material in the resulting
lysates was analyzed by scintillation counting. Data were expressed as
percentage of control.
Colorimetric assay. Chub-S7 preadipocytes were seeded into a
96-well plate (1  104 cells/well). Following overnight culture, cells
were pretreated for 2 h with the estrogen receptor antagonist faslodex,
the androgen receptor antagonist flutamide (both 100 nM; Sigma-
Aldrich), the glucocorticoid receptor RU-486 (5 M; Sigma-Aldrich),
cortisol, or cortisone (both 500 nM; Sigma-Aldrich) before treatment
with DHEA (25 M). At 24, 72, and 120 h, cell proliferation was
assessed utilizing a nonradioactive cell proliferation assay (Promega,
Madison, WI) according to the manufacturer’s protocol. Lumines-
cence was recorded at 490 nm utilizing a plate reader. Data were
expressed as percentage of control.
Cell cycle analysis by flow cytometry. Chub-S7 cells were seeded
into a six-well plate (6  105 cells/well). Following overnight culture,
cells were incubated with 25 M DHEA. After 3 days, cells were
incubated with propidium iodide (50 g/ml) in phosphate citrate
buffer containing 0.2 M Na2HPO4 and 0.1 M citric acid (24:1, pH 7.8,
all Sigma-Aldrich) for 30 min. Samples were analyzed using a FACS
IV flow cytometer at a wavelength of 488 nm. Approximately 10,000
cells per injection were analyzed.
mRNA Expression Analysis
RNA extraction and RT. RNA extraction was performed on
Chub-S7 preadipocytes differentiated in the presence of DHEA (0–25
M) for 7, 14, and 21 days as well as on the other tissues used in the
Chub-S7 cell model validation experiment (see above). Total RNA
was extracted using TRI-reagent (Ambion/Life Technologies, Grand
Island, NY) according to the manufacturer’s protocol.
Qualitative mRNA analysis. Expression analysis of steroidogenic
genes and steroid transporters was carried out using the gene-specific
primers shown in Table 1. Amplifications were carried out at 95°C for
30 s, 60°C for 30 s, and 72°C for 30 s in a 20-l final volume for 30
cycles.
Quantitative real-time mRNA analysis. The mRNA expression of
adipocyte differentiation markers [lipoprotein lipase (LPL), G3PDH,
FABP4, and UCP1] and genes that regulate the local amplification of
glucocorticoids (HSD11B1, H6PDH) was determined using an ABI
7500 sequence detection system (Applied Biosystems/Life Technol-
ogies). For the Chub-S7 model validation experiments, gene expres-
sion in Chub-S7 cells was analyzed on days 0 (confluent, not differ-
entiated) and 14 (differentiated). For all other experiments, gene
expression was analyzed on days 7, 14, and 21 in cells differentiated
with cortisone and on days 8 and 16 for cells differentiated with
cortisol. Previous preliminary experiments confirmed that on days 14
and 21 differentiated with cortisone and days 8 and 16 differentiated
with cortisol, cells had reached comparable differentiation states
(assessed lipid accumulation and CT values of differentiation mark-
ers) due to the greater differentiation capacity of the active steroid.
Reactions were performed in 20-l volumes on 96-well plates using
2 TaqMan Universal PCR Master Mix (Applied Biosystems/Life Tech-
nologies). Expression-specific probes and primers were supplied by
Applied Biosystems as “assay on demand” reagents for the analysis of
LPL, G3PDH, SULT2A1, STS, and AKR1C3 and as proprietary primers
for FAB4 and UCP1. For analysis of HSD11B1 and H6PDH, specific
primers and probes were designed (Table 2). All reactions were normal-
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ized against the housekeeping gene 18S rRNA. Data were expressed as
CT values and used to determine CT values and fold changes using the
following equation: fold increase  2CT.
Enzyme Activity Assays
DHEA metabolism assay. Chub-S7 cells were incubated in DMEM
containing cold DHEA (20 nM) and tritiated DHEA (0.2 Ci/well) for
48 h. Following incubation, steroids were extracted using dichloro-
methane separated by thin-layer chromatography using n-hexane/1-
hexanol (75:25; both Sigma-Aldrich) as the mobile phase system.
Metabolites were identified by comigration with unlabeled reference
steroids that were visualized by exposure to Lieberman-Burchard
reagent (ethanol-acetic anhydride-sulfuric acid). Steroid conversion
was quantified using a LabLogic AR-200 scanner (LabLogic, Shef-
field, UK). Protein concentration was measured using a colorimetric
96-well plate assay (Bio-Rad, Hemel Hempstead, UK) and used to
normalize conversion. Activity was expressed as percent conversion.
11-HSD1 activity assay. Cells were cultured for 21 days in
DMEM supplemented with DHEA. 11-HSD1 oxoreductase and
dehydrogenase activity were assessed as described previously (5).
Briefly, cells were incubated with 100 nM cortisol or cortisone with
appropriate tritiated tracer-[3H]cortisol (F) or [3H]cortisone (E) (0.02
Ci/reaction). Following incubation, steroids were extracted, sepa-
rated, and quantified as above, utilizing chloroform and ethanol (92:8)
as the mobile phase. Activity was expressed as cortisol or cortisone
production in picomoles per milligram of protein per hour.
Glucose Uptake Assay
Differentiated adipocytes were incubated with serum-free DMEM
for 12 h prior to the addition of DHEA (final concentration 0–25 M)
for 2 h. Glucose uptake activity was assessed by measuring the uptake
of 2-deoxy-D-[3H]glucose, as described previously (19). Analysis was
performed in the presence or absence of 20 nM insulin. Data were
expressed as percentage of control based on the measured disintegra-
tions per minute.
Statistical Analysis
Where data were normally distributed, the unpaired Student t-test was
used to compare single treatments with control. If normality tests failed,
then nonparametric tests were used. One-way ANOVA on ranks was
used to compare multiple treatments, doses, or times (SigmaStat 3.1;
Systat Software, Point Richmond, CA). Statistical analysis of real-time
PCR data was performed on mean CT values and not transformed fold
changes.
RESULTS
Chub-S7 Cell Model Validation
Real-time mRNA expression of UCP-1 in undifferentiated
Chub-S7 cells was very low (0.00004  0.00001 AU) and
remained very low following differentiation (0.00002 
0.000004 AU) (Fig. 1A). In direct comparison, UCP-1 expres-
sion in mouse BAT was 10-fold higher (10.6  2.5 AU).
Overall, UCP-1 expression in Chub-S7 cells before and after
differentiation was low comparared with the other non-BAT
tissues examined, i.e., human mature subcutaneous adipocytes
(0.00016  0.00004 AU) and hepatocytes (0.00001  0.00001
AU) (Fig. 1A). DHEA treatment of human primary preadi-
pocytes did not have any effect on UCP-1 expression (Fig. 1A).
The white adipose tissue marker FABP4 was undetectable in
undifferentiated Chub-S7 cells but was expressed at levels
comparable with human mature adipocytes (2.4  0.9 vs.
2.3  0.0001 AU) following differentiation (Fig. 1B). Treat-
ment of human primary preadipocytes with either 100 nM or
10 M DHEA did not have any effect on FABP4 expression
(control: 0.43  0.06 AU; 100 nM DHEA: 0.38  0.003 AU;
10 M DHEA: 0.24  0.02 AU; Fig. 1B).
Table 1. Qualitative mRNA analysis primers
Gene Forward Primer Reverse Primer
SULT2A1 CAGGAAGAACCATAGAGAAGATCTG GTCTTACACAATGACCCCAGTC
STS AGGACTTCCCACCGATGAGATTACCTTTG AAAAGGGTCAGGATTAGGGCTGCTAGGAA
HSD11B1 ACCAGAGATGCTCCAAGGAA ATGCTTCCATTGCTCTGCTT
OATP-A CCACAAGATTTATATGTGGAAAATG CATATATCCAGGTATGGCAGCC
OATP-B CATGGGACCCAGGATAGGGCCA GGCCTGGCCCCATCATGGTCACTG
OATP-C GTTCAACCTGAATTGAAATCAC GATGTGGAATTATATGTCCTACATGAC
OATP-D GCTGAGAACGCAACCGTGGTTCC GACTTGAGTTCAGGGCTGACTGTCC
OATP-E GCCATGCCACTGCAGGGAAATG TTCTGGTACACCAAGCAGGAGCCC
OATP-F CAGAAAGACAATGATGTCC CACATCTTTTAAATCCCCATTTGAGGC
OATP-8 GAATAAAACAGCAGAGTCAGCATC GCAATATAGCTGAATGACAGG
OAT-4 CTCTGCGGTTTCCACAAACATGACC CCACCATCAGTGTCAGTGAACTCAG
AKR1C3 ACTTCATGCCTGTATTGGGATTTG CTGCCTGCGGTTGAAGTTTGATA
HSD17B4 AGTTCTCTCTCTTTCTTGTTGGCTCTGGA GCGTCCTATTTCCTCAAATACAAAGGTACTCT
HSD3B1 GGAATCTGAAAAACGGCGGC CTGAGATATAGTAGAACTGTCCTCGGATG
HSD3B2 GATCGTCCGCCTGTTGGTG CTCTTCTTCGTGGCCGTTCTGGATGAT
SULT2A1, DHEA sulfotransferase; STS, steroid sulfatase; HSD11B1, 11-hydroxysteroid dehydrogenase type 1; OATP, organic anion polypeptide; OAT-4,
organic anion transporter 4; AKR1C3, 17-hydroxysteroid dehydrogenase type 5; HSD17B4, 17-hydroxysteroid dehydrogenase type 4; HSD3B, 3-
hydroxysteroid dehydrogenase.
Table 2. Real-time mRNA analysis primers and probes
Gene Forward Primer Reverse Primer Probe
HSD11B1 AGGAAAGCTCATGGGAGGACTAG ATGGTGAATATCATCATGAAAAAGATTC CATGCTCATTCTCAACCACATCACCAACA
H6PDH CAGGTGTCCTAGTGCACATTGAC GTAGCCCACTCTCTCGTCCAA AAGGCACGCCCTCCCAGCG
GPD1 (G3PDH) AGGGCCATCTGAAGGCAAACGCC CCATCAGTTCATCGGCAAGAT TCGTCTACCCCCTTAATAAGAGATATG
H6PDH, hexose-6-phosphate dehydrogenase; GPD1, glycerol-3-phosphate dehydrogenase.
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DHEA Metabolism in Human Preadipocytes and Adipocytes
Real-time mRNA expression analysis of key DHEA-metabo-
lizing enzymes (Fig. 2A) in Chub-S7 cells and human subcutane-
ous primary adipocytes revealed no expression of SULT2A1,
indicating that DHEA cannot be inactivated by sulfation to
DHEAS within preadipocytes or adipocytes (Fig. 2B). In con-
trast, abundant expression of STS, which catalyzes the oppos-
ing reaction, was detected in all samples (Fig. 2B). We iden-
tified selective expression of OATP-D, an influx transporter of
hydrophilic DHEAS (Fig. 2B), suggesting that DHEAS can
actively enter the adipocyte.
Whereas mRNA expression of HSD3B1 or HSD3B2 was not
detected, we observed expression of AKR1C3, encoding 17-
HSD type 5, in all samples (Fig. 2B). Quantitative mRNA
expression analysis revealed that expression of AKR1C3 was
relatively low in preadipocytes but greatly increased following
adipocyte differentiation (Fig. 2C).
Functional assays utilizing radiolabeled DHEA revealed
that, consistent with the above finding, there is significant
conversion of DHEA to androstenediol in fully differentiated
adipocytes (Fig. 2D). In contrast, there was no appreciable
conversion of DHEA in preadipocytes (Fig. 2D). Interestingly,
despite the detection of mRNA transcripts encoding STS in
both preadipocytes and mature adipocytes, we did not detect
any conversion of DHEA and DHEAS, demonstrating a lack of
functional activity of STS (data not shown).
Effects of DHEA on Preadipocyte Proliferation
Because the acquisition of adipose mass in vivo requires
both preadipocyte proliferation and differentiation, we exam-
ined the effects of DHEA on both of these processes. DHEA
(1 M) caused a dose-dependent inhibition of Chub-S7
proliferation, as assessed by thymidine incorporation assays
(Fig. 3A). Androstenediol (10 M) had less effect, and
DHEAS had no effect at all on Chub-S7 proliferation (Fig. 3,
B and C). Coincubation with the estrogen receptor antagonist
faslodex and the androgen receptor antagonist flutamide failed
to reverse the inhibitory effect of DHEA on Chub-S7 prolif-
eration (Fig. 3D), indicating that DHEA does not act via these
receptors. Furthermore, coincubation with either cortisol or
cortisone did not reverse the DHEA effect (Fig. 3D). Interest-
ingly, coincubation with the glucocorticoid receptor antagonist
RU-486 resulted in an additive inhibitory effect on Chub-S7
proliferation (Fig. 3D). Experiments using human primary
subcutaneous preadipocytes confirmed that DHEA (1 M)
inhibited preadipocyte proliferation (Fig. 4A).
We hypothesized that the inhibitory effect of DHEA was due
to aberrant cell cycle progression and carried out FACS cell
B
A
Fig. 1. Chub-S7 cell line validation. A: quantitative
real-time PCR mRNA expression of the brown adipose
tissue (BAT) marker uncoupling protein 1 (UCP1) in
Chub-S7 preadipocytes (Chub Pre; n  3) and differ-
entiated Chub-S7 adipocytes (Chub Adip; n  3),
mature human subcutaneous adipocytes (Sc Adip; n 
8), human primary differentiated preadipocytes with-
out (Sc Pre Ctr; n  3) or with dehydroepiandrosterone
(DHEA) (Sc Pre DHEA; 100 nM and 10 M, each n 
3), human primary hepatocytes (Hep; n  4), mouse
BAT (mBAT; n  3), mouse white adipose tissue
(mWAT; n  4), and hepatocytes (mHep; n  3).
B: mRNA expression of the white adipose tissue
marker fatty acid-binding protein 4 (FABP4) in
Chub-S7 and human tissues as before. Chub-S7 cells,
similarly to other non-BAT tissues, did not express any
substantial amounts of UCP1 but showed FABP4 ex-
pression similar to white adipose tissue. Data ex-
pressed as mean arbitrary units (AU)  SE from
triplicate measurements. STS, steroid sulfatase.
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cycle analysis of Chub-S7 cells. Results revealed that DHEA
caused a significant increase in the G1 phase while concur-
rently significantly reducing the proportion of cells in G2 and
S phase (Fig. 4B).
Effects of DHEA on Preadipocyte Differentiation
The effect of DHEA on preadipocyte differentiation was
assessed by observing cell morphology and mRNA analysis of
the expression of differentiation markers. Treatment with 25
M DHEA resulted in the cells appearing more fibroblast like,
with less lipid accumulation, whereas no morphological differ-
ences were observed at lower concentrations (Fig. 5A). DHEA
coincubated with cortisone caused a dose-dependent inhibition
of the mRNA expression of early and terminal differentiation
markers LPL (10 M) and G3PDH (10 M), respectively
(Fig. 5B). Androstenediol treatment resulted in less pro-
nounced retardation of gene expression (LPL, G3PDH, 25
M; data not shown), and DHEAS did not demonstrate any
effect (data not shown).
To test whether DHEA interferes with the PPAR	 pathway,
especially in view of the use of rosiglitazone in the Chub-S7
differentiation media, we differentiated Chub-S7 cells in the
presence or absence of rosiglitazone in media containing 10 nM
DHEA. Expectedly, addition of rosiglitazone resulted in an almost
ninefold induction of fatty acid synthase (FASN), a marker of
WAT differentiation (Fig. 5C). Furthermore, the presence of
DHEA did not inhibit PPARG expression (Fig. 5C).
Effects of DHEA on Adipocyte 11-HSD1 Expression
and Activity
DHEA treatment inhibited expression of the key glucocor-
ticoid-regulating genes H6PDH (100 nM) and HSD11B1
(1 M) in differentiating preadipocytes in a dose-dependent
manner (Fig. 5B). In keeping with this finding, DHEA treat-
SULT2A1
STS
AKR1C3
OATP D
Om    Om Sc     Sc Chub  Chub
Pre   Adip Pre   Adip Pre    Adip Neg Pos
DHEAS
DHEA
Androstenediol
Androstenedione Estrone
Testosterone Estradiol
DHT
Co
nv
er
sio
n 
of
 
DH
EA
 
to
 
an
dr
os
te
n
ed
io
l 
(pm
o
l/m
g 
pr
ot
ei
n
/h
r)
*
18S
-
*
*
*
A
B
C D
Fig. 2. DHEA is metabolized to androstenediol in
Chub-S7 adipocytes. A: schematic overview of
key pathways of DHEA metabolism to DHEAS
(sulfate ester of DHEA) and downstream steroids
by steroidogenic enzymes. B: representative con-
ventional PCR analysis of mRNA expression of
steroidogenic genes in human omental preadi-
pocytes (Om Pre) and adipocytes (Om Adip), Sc
Pre and Sc Adip, and Chub Pre and Chub Adip.
C: quantitative real-time PCR mRNA expression
analysis of AKR1C3 in Om Pre and Om Adip, Sc
Pre and Sc Adip, and Chub Pre and Chub Adip.
Expression analysis confirmed the expression of
AKR1C3 in Chub-S7 and human adipose tissue,
which was increased in differentiated adipocytes
relative to preadipocytes. Data are expressed as
means  SE of 3 independent triplicate experi-
ments. D: Chub-S7 cells were incubated with
[3H]DHEA for 24 h. Appreciable conversion of
DHEA to androstenediol was observed in adi-
pocytes but not proliferating preadipocytes (*P 

0.05 compared with preadipocytes).
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ment (1 M) resulted in a marked reduction in 11-HSD1
oxoreductase activity (1 M; Fig. 6A) and a concurrent
increase in dehydrogenase activity at the highest DHEA dose
used (25 M DHEA; Fig. 6B) in differentiated adipocytes.
Again, DHEAS had no effect, and androstenediol had a lesser
effect (data not shown).
Functional Significance of DHEA Mediated Inhibition of
11-HSD1
We postulated that the inhibition of 11-HSD1 activity may
account for the observed inhibitory effect of DHEA on prea-
dipocyte differentiation. To test this hypothesis, we analyzed
the effect of DHEA on adipocytes differentiated in the pres-
ence of the active glucocorticoid cortisol, negating the require-
ment for 11-HSD1 activity for differentiation. In these cul-
tures, the inhibitory effect of DHEA on mRNA expression of
differentiation markers was significantly diminished (Fig. 6C).
At 10 M DHEA, LPL expression was reduced by 52% in
differentiation assays with cortisone compared with 28% when
coincubated with cortisol; similar effects were observed for
G3PDH (DHEA  cortisone 68%, DHEA  cortisol 37%) and
HSD11B1 (DHEA  cortisone 68%, DHEA  cortisol 43%)
(Fig. 6C). Interestingly, coincubation with cortisol did not
significantly alter the level of DHEA-induced inhibition of
H6PDH expression (Fig. 6C).
Effects of DHEA on Adipocyte Glucose Uptake
DHEA significantly increased basal glucose uptake (P 

0.05 for 10 and 100 M DHEA; Fig. 7A) in mature Chub-S7
adipocytes. Interestingly, insulin-stimulated glucose uptake
was not affected by the addition of DHEA (Fig. 7A). We
confirmed the validity of this result employing human primary
subcutaneous preadipocytes, which demonstrated comparable
results using a 25-M DHEA concentration (Fig. 7B). Com-
pared with basal, insulin increased glucose uptake to 125 
8.6% (P 
 0.05) and DHEA to 115  10.7% (P 
 0.05).
Fig. 3. Dose-dependent inhibition of Chub-S7 preadipocyte proliferation by
DHEA and androstenediol. Subconfluent Chub-S7 preadipocytes were incubated
with DHEA, androstenediol, or DHEAS (0–100 M) for 24, 48, or 72 h. A and
B: proliferation was analyzed by incubation with 0.2 Ci of [3H]thymidine for the
last 6 h of culture. C: DHEA (1 M; A) and androstenediol (10 M; B)
significantly inhibited preadipocyte proliferation. DHEAS did not significantly
affect proliferation. D: the inhibitory effect of DHEA was not diminished when
cells were coincubated with antagonists of the androgen receptor flutamide, the
estrogen receptor faslodex, the glucocorticoid receptor RU-486, cortisol (F), and
cortisone (E). Data represent means  SE (A–C) or %control (D) obtained from
at least 3 independent experiments. In A–C, *P 
 0.05 and **P 
 0.01. In D,
*P 
 0.05 vs. control and #P 
 0.05 vs. DHEA.
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 0.05.
DPM, disintegrations per minute.
E1139DHEA INHIBITS 11-HSD1 IN HUMAN ADIPOCYTES
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00314.2012 • www.ajpendo.org
Addition of insulin to DHEA increased glucose uptake to
133  14.0% compared with DHEA alone (P 
 0.05).
DISCUSSION
We have validated the Chub-S7 cell model and have con-
firmed that it is representative of human subcutaneous white
adipose tissue, as described before (6). Thiozolidinediones
(TZDs) are known to induce a BAT-like phenotype in human
preadipocytes (15). We investigated whether the use of the
TZD rosiglitazone during the Chub-S7 differentiation process
could have altered the cellular phenotype. Our findings indicate
that TZD treatment of Chub-S7 cells does not result in any
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Fig. 5. DHEA inhibits preadipocyte differentiation but
not PPARG expression. A: morphological changes dur-
ing differentiation of Chub-S7 cells (image A) are
attenuated by DHEA treatment. Confluent Chub-S7
preadipocytes were differentiated in chemically de-
fined media for 21 days in the presence of DHEA
(0–50 M). Control cells (image B) displayed a
differentiated morphology with the acquisition of
lipid droplets and the loss of a fibroblast-like appear-
ance. Cells treated with 10 M DHEA (image C) did
not appear to differ morphologically from control
cells. In contrast, cells treated with 25 M DHEA
(image D) appeared more fibroblast like than control
cells, with an elongated shape, and contained much
fewer lipid droplets. B: Chub-S7 cells were differen-
tiated in the presence of DHEA (0–25 M) and 500
nM cortisone for 21 days. mRNA expression analysis
is presented at the time point where the most signif-
icant effect of DHEA was observed: LPL and
H6PDH, day 14; G3PDH and 11-HSD1, day 21.
mRNA expression was determined by quantitative
PCR analysis and expressed as fold change of control.
Data was obtained from at least 3 independent exper-
iments C: Chub-S7 cells were differentiated for 14
days in the presence of DHEA (10 nM) and with or
without the addition of 1 M rosiglitazone. Expres-
sion of white adipose tissue differentiation marker
FASN increased with the addition of rosiglitazone,
but DHEA did not result in inhibition of PPARG
expression. Data obtained from 3 independent exper-
iments; differences in expression did not reach statis-
tical significance. *P 
 0.05.
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relevant UCP-1 expression, which was similar to the extremely
low levels found in other non-BAT tissues.
We have found that DHEA exerts antiglucocorticoid action
at several levels in adipose tissue, including adipogenesis and
basal glucose uptake. Previous studies have shown that the
expression and activity of 11-HSD1 is inhibited by DHEA in
murine adipocytes (2, 43) and rat liver (22), suggesting a
mechanistic link between DHEA and glucocorticoids, but the
functional significance of this finding was previously un-
known. Here, we have shown that inhibition of 11-HSD1
contributes significantly to attenuation of preadipocyte differ-
entiation mediated by DHEA.
We have demonstrated a clear inhibitory effect of DHEA on
preadipocyte differentiation, characterized by attenuation of the
expression of differentiation markers, morphological changes, and
lipid accumulation. This is in line with previous studies alluding to
an inhibitory effect of DHEA on preadipocyte differentiation.
Lea-Curie et al. (33) observed that DHEA attenuated triacyl-
glycerol accumulation in differentiating 3T3-L1 cells. Kajita et
al. (29) have reported that DHEA treatment of rodents de-
creased the expression of PPAR	, a regulator of adipocyte
differentiation, in the adipose tissue of these animals. More
recently, it was shown that DHEA reduces body weight and
epididymal fat in a murine model of obese type 2 diabetes (18).
Interestingly, it was shown that although DHEA does not affect
differentiation of human primary subcutaneous preadipocytes,
it has inhibitory effects on proliferation and differentiation of
omental preadipocytes (39). However, all of these previous
studies have failed to provide clear mechanistic insights into
the effects of DHEA.
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Fig. 6. DHEA attenuates preadipocyte differentiation via
inhibition of 11-hydroxysteroid dehydrogenase type 1
(11-HSD1) oxoreductase activity. A and B: cells differ-
entiated for 21 days in the presence of DHEA (0–25
M) were incubated with serum-free DMEM contain-
ing 100 nM cortisone and 50,000 cpm/ml [3H]cortisone
for 3 h. Individual well protein concentrations were
calculated and used as an internal control. DHEA (1
M) significantly inhibited 11-HSD1 oxoreductase
activity (A) and increased dehydrogenase activity (B).
Data are expressed as means  SE of 3 independent
triplicate experiments. C: Chub-S7 cells were differen-
tiated in the presence of DHEA (0–25 M) and 500 nM
cortisone (black bars) or 500 nM cortisol (open bars).
mRNA expression analysis is presented at the time
point where the most significant effect of DHEA coin-
cubated with cortisone was observed: LPL and H6PDH,
day 14; G3PDH and 11-HSD1, day 21. mRNA ex-
pression was determined by quantitative PCR and ex-
pressed as %decrease in control. Data were obtained
from 3 independent experiments. Statistical analysis
was performed on CT values. DHEA (10 M), when
coincubated with inactive cortisone, significantly inhib-
ited LPL, G3PDH, and 11-HSD1 expression to a
greater extent than when coincubated with active corti-
sol. In contrast, there was no significant difference in
H6PDH expression between treatments. *P 
 0.05 and
**P 
 0.01 vs. control.
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We have shown that the inhibitory effect of DHEA on
preadipocyte differentiation is via an antiglucocorticoid mech-
anism. It is well characterized that glucocorticoids, reactivated
locally by the oxoreductase activity of 11-HSD1, play a vital
permissive role in inducing preadipocyte differentiation (7, 21,
24, 48). In addition, the selective inhibition of 11-HSD1 in
human primary preadipocytes and Chub-S7 cells impairs the
differentiation of these cells (6). We have demonstrated that
DHEA attenuates the local regeneration of glucocorticoids in
adipocytes and have shown this is via two concerted mecha-
nisms: attenuation of the induction of 11-HSD1 during dif-
ferentiation and inhibition of expression of H6PDH, the en-
zyme that regenerates the cofactor NADPH that is required for
11-HSD1 oxoreductase activity (25). We have demonstrated
that inhibition of expression of these genes has physiological
significance, inhibiting the local amplification of glucocortico-
ids resulting in the attenuation of the differentiation of preadi-
pocytes. Furthermore, via coincubation assays with the active
glucocorticoid cortisol, we have demonstrated conclusively
that it is via 11-HSD1, at least in part, that DHEA mediates
the inhibition of adipocyte differentiation. However, it is clear
that DHEA acts additionally via glucocorticoid-independent
mechanisms since coincubation with cortisol still resulted in
inhibition of preadipocyte differentiation, albeit significantly
diminished.
A previous study employing a murine model has suggested
that DHEA-dependent effects may be mediated via the andro-
gen receptor (18). This is in contrast to our findings, as we
could not demonstrate any androgen receptor-mediated DHEA
effects in human preadipocytes with no evidence of the rever-
sal of the inhibitory effects of DHEA when coincubating with
the androgen receptor antagonist flutamide.
It is as yet unknown whether DHEA inhibits 11-HSD1
gene expression directly or via a regulator of 11-HSD1
expression such as the adipogenic gene C/EBP (1), which
may account for the remaining inhibitory effect of DHEA upon
coincubation with cortisol. Others have shown that murine
adipocyte DHEA acts as a noncompetitive inhibitor of 11-
HSD1 independently of transcriptional control (43).
One limitation of our study is the use of TZDs during the
differentiation process of our model cell line. TZDs are known to
promote adipogenesis via PPAR	-mediated pathways, whereas
the PPAR	 gene locus PPARG is regulated by C/EBPs and the
glucocorticoid receptor (13). Although it is clear that TZDs are
important differentiation determinants in our model cell line,
we could show that DHEA does not inhibit PPARG expression
in our model. Hence, it seems unlikely that the observed
inhibitory effects of DHEA on differentiation are due to inter-
ference with the TZD/PPAR	 pathway. Clearly, more studies
exploring the exact mechanistic effects of DHEA on adipocyte
differentiation are warranted.
The effect of DHEA is specific, as neither DHEAS nor the
principal metabolite of DHEA in adipocytes, androstenediol
(19), produced comparable inhibitory effects. Conversion of
DHEA in preadipocytes is negligible, and in support of spec-
ificity, detection of OATP-D, an influx transporter of DHEAS
(38), suggests that the lack of effect of DHEAS is not due to its
inability to enter the cell.
In addition to the inhibitory effect of DHEA on preadipocyte
differentiation, we have demonstrated that DHEA significantly
attenuates preadipocyte proliferation and increases basal adi-
pocyte glucose uptake. Some of these findings have been
described previously, utilizing murine models (1, 18, 43).
However, because mice do not produce DHEA physiologi-
cally, the validity of these results to humans was previously
unclear. Our study demonstrates conclusively that DHEA has
similar effects on adipocyte biology in murine and human
cells, suggesting that DHEA may have beneficial effects in
vivo. Further human in vivo studies are warranted, especially
since DHEA effects on different metabolic tissues have been
described.
Our observation that DHEA results in preadipocyte prolif-
eration through arrest in the G1 phase of the cell cycle is
consistent with earlier murine studies utilizing 3T3-L1 cells
(20, 32, 34) and human preadipocytes (39). This effect is in
contrast to glucocorticoids, which are known to stimulate
subcutaneous preadipocyte proliferation in a depot-specific
manner (3). From a mechanistic point of view, the DHEA-
A
B
Fig. 7. DHEA increases basal but not insulin-dependent glucose uptake in
adipocytes. A: in mature Chub-S7 adipocytes, DHEA (1 M) significantly
increased basal glucose uptake (black bars) but not insulin-stimulated glucose
uptake (20 nM; gray bars). B: in human primary adipocytes, insulin increased
glucose uptake to 125  8.6% (P 
 0.05) and 25 M DHEA to 115  10.7%
(P 
 0.05) compared with basal. Addition of insulin to DHEA increased
glucose uptake to 133  14.0% compared with DHEA alone (P 
 0.05). Data
are presented as %control from 5 experiments performed in triplicate [Chub-S7
control DPM  5,257 (A); human primary adipocytes control DPM  5,212
(B)]. *P 
 0.05 vs. control; #P 
 0.05 vs. DHEA treatment.
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mediated inhibition of preadipocyte proliferation appears to be
independent of the androgen and estrogen receptor-mediated
action. Moreover, the finding that, in contrast to preadipocyte
differentiation, replacement of inactive cortisone by cortisol
does not result in an attenuation of the DHEA effect suggests
an antiproliferative mechanism that is independent of 11-
HSD1. This is further supported by the observed additive effect
after coincubation with the glucocorticoid receptor antagonist
RU-486 on preadipocyte proliferation. However, it must be
noted that RU-486 not only is a glucocorticoid receptor antag-
onist but has additional actions, e.g., at the progesterone
receptor. Thus we cannot exclude other mechanisms resulting
in the observed additive effects.
We have shown DHEA to stimulate basal glucose uptake,
mimicking the action of insulin, consistent with the ameliora-
tion of hyperglycemia and insulin resistance observed upon
DHEA treatment in vivo (47). Again, this effect of DHEA
opposes that of glucocorticoids, which induce insulin resis-
tance in preadipocytes (41, 46). The underlying mechanisms by
which glucocorticoids modulate insulin signaling remain un-
clear but appear to involve the conventional protein kinase C
(PKC) (27, 30). In direct contrast, it has been demonstrated
utilizing rat adipocytes that DHEA may mimic insulin action
via PI3K and atypical PKC activation (26) independent of the
insulin receptor or Akt activation, resulting in increased trans-
location of the glucose transporters GLUT1 and GLUT4 to the
plasma cell membrane (37). These findings are consistent with
the rapid stimulatory effect of DHEA on basal glucose uptake
observed in this study, which suggests that DHEA is acting via
a nongenomic mechanism. However, further studies are re-
quired to elucidate the exact mechanism underlying the ob-
served DHEA effects on glucose uptake.
Our findings indicate the likelihood of favorable metabolic
effects of DHEA in vivo as it opposes the effects of glucocor-
ticoids by distinct mechanisms. The adverse metabolic effects
of glucocorticoids are well characterized and exemplified in
patients with Cushing’s syndrome (8). Transgenic mice over-
expressing 11-HSD1 under control of the aP2 promoter
display the full-blown metabolic syndrome, including increased
adiposity (36). Conversely, knockdown of 11-HSD1 in mice
results in protection from high-fat diet-induced development of
the metabolic syndrome, including reduced adiposity and im-
proved insulin sensitivity (31). The inhibition of 11-HSD1 ac-
tivity or activation of opposing pathways could have beneficial
effects in vivo. Indeed, selective inhibition of 11-HSD1 activity
is emerging as an exciting, novel therapeutic approach in type 2
diabetes and the metabolic syndrome (40).
Our findings establish that DHEA inhibits human subcuta-
neous adipogenesis and increases glucose uptake in vitro,
actions that oppose those of glucocorticoids. Our findings are
in keeping with the significant increase in glucose sensitivity
and reduction in adiposity reported by Villareal and Holloszy
(47) in elderly subjects treated with 50 mg/dl DHEA for 6 mo.
However, antiglucocorticoid action of DHEA is metabolically
counteracted by its androgenic action, which can also yield
unfavorable metabolic consequences. Further studies to eluci-
date the effects of DHEA on human metabolism and adipose
tissue function are warranted to unravel the regulatory mech-
anisms underlying the delicate balance between glucocorticoid
and androgen action.
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